Ionizable Lipid Nanoparticles for Extrahepatic Therapeutic Delivery
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing lipid nanoparticle compositions struggle to deliver therapeutic agents effectively to endothelial cells, mesenchymal cells, or cancer cells in organs other than the liver, despite advancements in liver-specific delivery.
Innovation Solution
A lipid composition comprising ionizable lipids and cholesterol derivatives with specific structures, such as those represented by formula (1), is used to enhance delivery efficiency to these cells in various organs.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If traditional ionizable cationic lipids are used for LNP formulation, then liver hepatocyte delivery is highly effective, but delivery to extrahepatic organs is not achieved
Solution Approach 1:
The patent changes the chemical parameters of the lipid composition by incorporating permanently cationic lipids with specific pKa values (7.0-8.0) and replacing traditional ionizable cationic lipids. This parameter change enables the LNP to maintain cationic charge at physiological pH, facilitating binding to negatively charged cell membranes in extrahepatic organs while preserving liver targeting capability through optimized lipid ratio composition.
Solution Approach 2:
The patent creates a composite lipid system combining permanently cationic lipids with neutral lipids (phospholipids, cholesterol, PEG-lipids) in specific ratios. This composite approach allows the LNP to exhibit both cationic interaction properties for broad tissue targeting and neutral lipid properties for stability and controlled release, achieving versatile delivery across multiple organ types.
2Reliability
If permanently cationic lipids are used to enhance extrahepatic delivery, then delivery to endothelial cells is improved, but cellular toxicity increases
Solution Approach 1:
The patent optimizes the pKa parameter of the cationic lipids to fall within 7.0-8.0, which is higher than traditional ionizable lipids (pKa 6.0-6.5). This parameter change ensures the lipids remain partially protonated at physiological pH, maintaining sufficient cationic charge for cell membrane interaction while reducing excessive protonation that causes toxicity. The patent also adjusts the molar ratio of cationic to neutral lipids to balance delivery efficiency and safety.
Solution Approach 2:
The patent applies local quality by creating lipids with specific structural features (formula (1) with basic functional groups) that provide cationic character only where needed for membrane interaction, while the rest of the lipid molecule maintains neutral properties. This localized cationic activity reduces overall toxicity while preserving delivery function at the cellular interface.
3Reliability
If ligand modification is used to target specific organs, then delivery specificity is improved, but manufacturing complexity increases
Solution Approach 1:
The patent extracts the targeting function from separate ligand modifications and integrates it directly into the lipid molecular structure itself. By incorporating basic functional groups (amino, aminoalkyl, guanidino, or heterocyclic) directly into the lipid head group, the targeting capability becomes an intrinsic property of the lipid rather than an added component, simplifying manufacturing while maintaining specificity.
Solution Approach 2:
The patent creates a universal lipid platform where the same basic lipid structure with integrated basic functional groups can target multiple organ types (liver, lung, heart, skeletal muscle, brain) by adjusting lipid composition ratios rather than requiring different ligand modifications for each target. This multi-functionality reduces manufacturing complexity by using a single lipid synthesis pathway for multiple applications.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The method achieves excellent delivery efficiency of therapeutic agents to endothelial cells, mesenchymal cells, or cancer cells in organs beyond the liver, ensuring safe and efficacious systemic and local delivery.
Implementation Method 1
A method for delivering a therapeutic agent to endothelial cells, mesenchymal cells, or cancer cells
Implementation Method 2
lipid nanoparticle comprises an ionizable lipid and a compound represented by formula (1)
Data Source
AI summary
The object of the present invention is to provide a method for delivering a therapeutic agent to endothelial cells, mesenchymal cells, or cancer cells which can realize excellent delivery efficiency to organs other than the liver, and a composition containing a therapeutic agent and lipid nanoparticles which can realize excellent delivery efficiency to an organ other than the liver. The present invention provides a method for delivering a therapeutic agent to endothelial cells, mesenchymal cells, or cancer cells, which comprises administering a lipid composition to a subject, wherein the lipid composition comprises the therapeutic agent and lipid nanoparticle,and wherein the lipid nanoparticle comprises an ionizable lipid and a compound represented by formula (1) or a salt thereof.wherein G1 represents —C(O)—, —OC(O)—, —O(CO)O— or —C(O)O—,LY represents a single bond, an alkylene group having 1-14 carbon atoms, a substituted alkylene group having 1-14 carbon atoms, a heteroalkylene group having 1-14 carbon atoms, and a substituted heteroalkylene group having 1-14 carbon atoms.X represents a basic functional group.